UK Real-World Evidence Posters in CLL
Explore UK real-world evidence posters which focus on CALQUENCE (acalabrutinib) use in CLL.
Adverse events should be reported
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.
September 2025 I GB-69434